BeOne Medicines AG (ONC) Q4 2025 Earnings Call Transcript

BRUKINSA: Achieved global leadership as the #1 BTK inhibitor in the U.S. and globally, with superior efficacy and safety data compared to competitors. Generated $3.9 billion in revenue in 2025, growing 49% year-over-year.

Sonrotoclax (Sonro): Achieved first global approvals in China for relapsed/refractory MCL and CLL. Regulatory submissions under review in the U.S. and EU, with FDA approval expected in the first half of 2026.

Zanidatamab (ZS): Positioned as a potentially best-in-class fixed-duration therapy for CLL, with promising clinical data showing high undetectable MRD rates and favorable safety profile.

U.S. Market: BRUKINSA achieved $845 million in Q4 sales, driven by 30% volume growth year-over-year. U.S. remains the largest market for BeOne.

China Market: Generated $399 million in Q4 revenue, supported by TEVIMBRA and BRUKINSA's market leadership.

Europe and Rest of World: Europe contributed $174 million in Q4 revenue, growing 53% year-over-year. Rest of World markets grew 74%, driven by market expansion and new launches.

Financial Performance: Achieved $1.5 billion in Q4 product revenue, with 32% year-over-year growth. Full-year 2025 revenue reached $6.2 billion, with GAAP profitability and $940 million in free cash flow.

R&D Advancements: Advanced 17 new molecules into the clinic over the past two years. Initiated multiple Phase III studies, including for BTK degrader and solid tumor therapies.

Clinical Execution: Completed 200 dose escalation cohorts in early-stage trials with a median of 1.5 months per cohort, significantly faster than industry norms.

CLL Innovation Goals: Outlined three aspirational goals for CLL innovation, including achieving life expectancy equal to the general population and developing superior fixed-duration therapies.

Solid Tumor Expansion: Shifted focus to critical oncogenic signaling pathways in breast, gynecological, lung, and gastrointestinal cancers, with five assets achieving proof of concept in 2025.

Global Clinical Development Super Highway: Enhanced clinical execution capabilities with AI and automation, enabling near real-time data analysis and faster trial completions.

Regulatory Hurdles: The FDA has not approved certain fixed-duration regimens like VI due to significant safety challenges, including higher death rates and severe infections. This limits the adoption of these therapies and poses a regulatory challenge for the company.

Competitive Pressures: BRUKINSA faces competition from other BTK inhibitors like ibrutinib, acalabrutinib, and pirtobrutinib. Although BRUKINSA has demonstrated superior efficacy and safety, the competitive landscape remains intense, requiring continuous innovation and differentiation.

Safety Concerns: Fixed-duration therapies like VO and VI have shown concerning safety profiles, including increased severe infections and higher death rates. These safety issues could impact patient and physician trust in these treatment options.

Market Adoption Challenges: Existing fixed-duration therapies have underwhelming efficacy and safety profiles, limiting their market adoption. This creates a challenge for BeOne to establish its fixed-duration regimens as viable alternatives.

Economic Uncertainties: The company’s financial performance is subject to economic conditions, including pricing dynamics and market expansion challenges in different geographies.

Strategic Execution Risks: The company is heavily investing in R&D and new product launches, which require flawless execution to achieve projected growth and market leadership. Any delays or failures in these areas could adversely impact performance.

Supply Chain Disruptions: Although not explicitly mentioned, the global nature of the company’s operations and product launches could expose it to potential supply chain disruptions, impacting product availability and revenue.

2026 Revenue Guidance: Projected revenue between $6.2 billion to $6.4 billion, driven by global leadership of BRUKINSA and contributions from new product launches.

BRUKINSA Growth: Continued strong demand growth in the U.S. with relatively stable net pricing. Expansion in all markets, including Rest of World markets.

New Product Launches: Modest initial contributions expected from launches of sonrotoclax and zanidatamab in 2026.

Gross Margin: Expected to remain in the high 80% range, benefiting from favorable product mix and productivity improvements.

Operating Expenses: Anticipated to be between $4.7 billion and $4.9 billion, supporting commercial growth and pipeline advancement.

GAAP Operating Income: Expected to range between $700 million and $800 million.

Non-GAAP Operating Income: Projected to be between $1.4 billion and $1.5 billion.

Income Taxes: Potential reversal of valuation allowance in 2026, which could result in a material tax benefit.

Pipeline Development: Focus on advancing CLL leadership, expanding hematological malignancies, establishing solid tumor leadership, and progressing immunology assets towards registration.

CLL Innovation: Development of fixed-duration regimens and continuous therapies, including ZS and BTK CDAC combinations, to address unmet needs.

Solid Tumor Strategy: Advancing five proof-of-concept assets towards registration, including CDK4/6 inhibitors, ADCs, and bispecifics.

Clinical Execution: Leveraging a global clinical development super highway to accelerate trial execution and regulatory filings.

The selected topic was not discussed during the call.